Pulse Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.2MTTM through 30 Jun 2026
Net Income -$80.1MTTM through 30 Jun 2026
Free Cash Flow -$61.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 7.7% |
| Operating Margin | -7,007.8% |
| Net Margin | -6,755.8% |
Returns
-112.5%ROE
-91.4%ROA
Balance Sheet Health
Debt / Equity0.11x
Current Ratio7.26x
Net Debt-$61.2Mnet cash position
Cash & Equivalents$101.6M
Quality Metrics
Altman Z-Score132.85
Piotroski F-Score2 / 9
FCF Margin-5,180.4%
Rule of 40-5,124.3
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $350K
Diluted EPSFY2025: $-1.08
Dividend
No dividend
Capital Allocation
Capex Intensity24.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Soft Tissue Ablation | $401K | View detailsThe company completed enrollment of the first 50 patients in the PRECISE-Benign Thyroid Nodule study and expanded potential enrollment to 100 patients. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.